Only Lipitor Has Demonstrated Significant LDL Reductions And Cardiovascular Benefits For A Wide Range Of Patients

Main Category: Cholesterol
Also Included In: Statins;  Cardiovascular / Cardiology
Article Date: 15 Mar 2006 - 0:00 PDT

email to a friend   printer friendly   opinions  

In response to inquiries from the news media about the ASTEROID trial for Crestor presented today at the American College of Cardiology, Pfizer issued the following statement:

-- Only Lipitor has demonstrated significant LDL reductions and cardiovascular benefits for a wide range of patients, with an excellent efficacy and safety profile across the full dose range.

-- This is not the first time a statin has demonstrated plaque regression. The REVERSAL trial compared treatment with Lipitor 80mg to another lipid lowering agent over 18 months. In a subset of high-plaque burden patients, Lipitor demonstrated a 5.9% (P<.001) total plaque reduction with excellent toleration.

-- It is not possible to compare the findings from ASTEROID with REVERSAL given ASTEROID's open label, single-arm design did not include a comparator. In contrast, Lipitor has demonstrated significant LDL and cardiovascular benefits in well controlled clinical trials such as PROVE IT, TNT and IDEAL.

-- Treatment practice has evolved significantly in the past several years, strongly supported by the results of the Lipitor clinical outcomes trials. Studies like PROVE IT, TNT and IDEAL have conclusively demonstrated the benefit of intensive lipid lowering with Lipitor.

-- The LDL levels reached in these studies, ranging from 60 to 80 mg/dL, are attainable only through intensive lipid lowering to a degree that cannot be matched with older, less efficacious therapies such as simvastatin.

-- Lipitor has a proven record of safety and over 115 million patient years of experience that cannot be matched by any other medicine.

-- Pfizer is using the IVUS technology in its large-scale Phase III torcetrapib/atorvastatin clinical trials program, which is studying some 25,000 patients at hundreds of medical centers worldwide.

-- The results from these trials, which will report out in the near future, will provide additional information on the lipid hypotheses alluded to in ASTEROID in a well-controlled manner.

Pfizer Inc
http://www.pfizer.com

• Additional
• References
• Citations